Submission of Un-audited Financial Results along with limited review report thereon for the Quarter and nine months ended on 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Limited reported a near-total collapse in revenue from operations, falling to just Rs 0.01 lakh in Q3 FY26 from Rs 241.43 lakhs in Q3 FY25. Total income for the quarter stood at around Rs 0.20 lakhs versus Rs 248.42 lakhs a year earlier, a drop of roughly 99%. The company slipped into a loss of approximately Rs 3.09 lakhs at the PAT level for the quarter and Rs 27.24 lakhs for the nine months ended December 2025, compared with a profit in the prior-year period and a full-year FY25 profit of Rs 16.39 lakhs. The statutory auditor (MAAK & Associates) issued a qualified opinion, noting that balance confirmations and supporting details for trade receivables and trade payables were not provided. The board reviewed and approved the results on 13 February 2026.
These results are significantly negative for shareholders — revenue has all but disappeared, the company is loss-making on a nine-month basis, and the auditor's qualified opinion over missing trade receivable/payable confirmations raises concerns about the reliability of the books. The stock is likely to face selling pressure and investors should treat this as a red flag.